334 related articles for article (PubMed ID: 33665940)
1. Certolizumab pegol in the treatment of psoriasis: Real-life data.
Turkmen M; Dogan S
Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Gordon KB; Warren RB; Gottlieb AB; Blauvelt A; Thaçi D; Leonardi C; Poulin Y; Boehnlein M; Brock F; Ecoffet C; Reich K
Br J Dermatol; 2021 Apr; 184(4):652-662. PubMed ID: 32652544
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
[No Abstract] [Full Text] [Related]
5. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
Warren RB; Lebwohl M; Sofen H; Piguet V; Augustin M; Brock F; C Arendt ; Fierens F; Blauvelt A
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2398-2408. PubMed ID: 34192387
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.
Umezawa Y; Asahina A; Imafuku S; Tada Y; Sano S; Morita A; Sakurai S; Hoshii N; Tilt N; Nakagawa H
Dermatol Ther (Heidelb); 2021 Jun; 11(3):943-960. PubMed ID: 33886085
[TBL] [Abstract][Full Text] [Related]
8. [Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Ruiz AN; Alberola FT; Aceituno S;
Farm Hosp; 2024; 48(2):T51-T56. PubMed ID: 38148255
[TBL] [Abstract][Full Text] [Related]
9. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J
J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
Vender RB; Lynde CW
J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
[TBL] [Abstract][Full Text] [Related]
12. Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Navarro Ruiz A; Toledo Alberola F; Aceituno S;
Farm Hosp; 2024; 48(2):51-56. PubMed ID: 37739901
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
Blauvelt A; Reich K; Lebwohl M; Burge D; Arendt C; Peterson L; Drew J; Rolleri R; Gottlieb AB
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):546-552. PubMed ID: 30242918
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Blauvelt A; Paul C; van de Kerkhof P; Warren RB; Gottlieb AB; Langley RG; Brock F; Arendt C; Boehnlein M; Lebwohl M; Reich K
Br J Dermatol; 2021 Apr; 184(4):640-651. PubMed ID: 32531798
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis.
Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC
Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928
[No Abstract] [Full Text] [Related]
16. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab pegol for the treatment of psoriasis.
Campanati A; Benfaremo D; Luchetti MM; Ganzetti G; Gabrielli A; Offidani A
Expert Opin Biol Ther; 2017 Mar; 17(3):387-394. PubMed ID: 28165828
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy.
Imafuku S; Tada Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H
Dermatol Ther (Heidelb); 2022 Jan; 12(1):121-135. PubMed ID: 34826124
[TBL] [Abstract][Full Text] [Related]
19. Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.
Umezawa Y; Sakurai S; Hoshii N; Nakagawa H;
Dermatol Ther (Heidelb); 2021 Apr; 11(2):513-528. PubMed ID: 33606269
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]